Security
Arbutus Biopharma Corporation Common Stock · ABUS
ABUSNASDAQCommon stockCurrentCIK 1447028Updated Oct 28, 2026
Name history
TEKMIRA PHARMACEUTICALS CORP · through Aug 3, 2015TEKMIRA PHARMACEUTICALS Corp · through Aug 3, 2015
ABUS price & chart
Loading TradingView…
NASDAQ:ABUS on TradingView ↗In the news
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer ↗
Recent filings
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding Arbutus Biopharma Corp
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by MORGAN STANLEY regarding Arbutus Biopharma Corp
4 filing
SC TO-I/A - filed by Arbutus Biopharma Corp regarding Arbutus Biopharma Corp
Show 5 more recent filings
SC TO-I/A - filed by Arbutus Biopharma Corp regarding Arbutus Biopharma Corp
4 filing
SCHEDULE 13G - filed by Whitefort Capital Management, LP regarding Arbutus Biopharma Corp
SC TO-I - filed by Arbutus Biopharma Corp regarding Arbutus Biopharma Corp
SC TO-C - filed by Arbutus Biopharma Corp regarding Arbutus Biopharma Corp
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 97,710,000Source | 140,441,000Source | 274,025,000Source | 103,267,000Source | 160,043,000Source | 277,164,000Source | 117,010,000Source | 150,290,000Source | 94,618,000Source | 131,707,000Source | 144,401,000Source | 195,419,000Source |
| Property, Plant and Equipment, NetUSD | 137,000Source | 3,556,000Source | 10,000Source | 148,000Source | 4,059,000Source | 22,000Source | 168,000Source | 4,414,000Source | 32,000Source | 3,309,000Source | 4,674,000Source | 5,070,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 22,408,000Source | 31,846,000Source | 19,171,000Source | 37,412,000Source | 62,788,000Source | 23,706,000Source | 37,076,000Source | 43,101,000Source | 18,008,000Source | 36,330,000Source | 26,285,000Source | 30,776,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 905,000Source | 1,608,000Source | 369,000Source | 1,025,000Source | 1,767,000Source | 1,312,000Source | 1,182,000Source | 2,139,000Source | 1,447,000Source | 2,409,000Source | 1,776,000Source | 1,352,000Source |
| Assets, CurrentUSD | 97,442,000Source | 132,777,000Source | 273,883,000Source | 103,119,000Source | 148,220,000Source | 277,011,000Source | 116,808,000Source | 135,872,000Source | 94,456,000Source | 127,316,000Source | 132,027,000Source | 151,139,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,835,000Source | 3,375,000Source | 1,516,000Source | 4,006,000Source | 4,467,000Source | 1,732,000Source | 2,919,000Source | 4,493,000Source | 1,538,000Source | 2,284,000Source | 4,248,000Source | 2,874,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 1,144,000Source | — | 0Source | 1,237,000Source | — | 0Source | 1,327,000Source | 0Source | 1,048,000Source | 1,416,000Source | 1,744,000Source |
| Other Assets, NoncurrentUSD | 131,000Source | — | 132,000Source | 0Source | — | 131,000Source | 34,000Source | — | 130,000Source | 34,000Source | 0Source | 103,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 20,311,000Source | 33,551,000Source | 15,292,000Source | 20,291,000Source | 37,589,000Source | 16,987,000Source | 37,853,000Source | 35,653,000Source | 18,042,000Source | 34,341,000Source | 38,383,000Source | 58,567,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,418,560,000Source | 1,407,595,000Source | 1,448,177,000Source | 1,417,110,000Source | 1,403,334,000Source | 1,444,494,000Source | 1,416,332,000Source | 1,377,315,000Source | 1,421,429,000Source | 1,410,025,000Source | 1,349,821,000Source | 1,318,737,000Source |
| Additional Paid in CapitalUSD | 83,285,000Source | 81,425,000Source | 74,321,000Source | 82,628,000Source | 81,751,000Source | 74,256,000Source | 82,089,000Source | 80,220,000Source | 83,318,000Source | 82,048,000Source | 81,270,000Source | 72,406,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,376,317,000Source | -1,334,040,000Source | -1,215,521,000Source | -1,368,575,000Source | -1,314,323,000Source | -1,210,378,000Source | -1,371,098,000Source | -1,294,527,000Source | -1,380,073,000Source | -1,346,572,000Source | -1,276,652,000Source | -1,203,803,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -48,129,000Source | -48,090,000Source | -48,244,000Source | -48,187,000Source | -48,308,000Source | -48,195,000Source | -48,166,000Source | -48,371,000Source | -48,098,000Source | -48,135,000Source | -48,421,000Source | -50,488,000Source |
| Stockholders' Equity Attributable to ParentUSD | 77,399,000Source | 106,890,000Source | 258,733,000Source | 82,976,000Source | 122,454,000Source | 260,177,000Source | 79,157,000Source | 114,637,000Source | 76,576,000Source | 97,366,000Source | 106,018,000Source | 136,852,000Source |
| Liabilities and EquityUSD | 97,710,000Source | 140,441,000Source | 274,025,000Source | 103,267,000Source | 160,043,000Source | 277,164,000Source | 117,010,000Source | 150,290,000Source | 94,618,000Source | 131,707,000Source | 144,401,000Source | 195,419,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,184,000Source | 18,923,000Source | 3,364,000Source | 5,022,000Source | 22,595,000Source | 5,105,000Source | 19,431,000Source | 20,296,000Source | 6,006,000Source | 15,618,000Source | 22,487,000Source | 32,857,000Source |
| Operating Lease, Liability, CurrentUSD | 531,000Source | 468,000Source | 514,000Source | 514,000Source | 453,000Source | 631,000Source | 563,000Source | 502,000Source | 547,000Source | 483,000Source | 425,000Source | 372,000Source |
| Operating Lease, Liability, NoncurrentUSD | 391,000Source | 978,000Source | 0Source | 575,000Source | 1,144,000Source | 0Source | 626,000Source | 1,181,000Source | 199,000Source | 806,000Source | 1,343,000Source | 1,815,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 91,500,000Source | 122,600,000Source | 132,300,000Source | 184,300,000Source |
| Deferred Revenue, CurrentUSD | 0Source | 10,911,000Source | — | 0Source | 11,034,000Source | — | 6,759,000Source | 11,547,000Source | 0Source | 7,571,000Source | 11,791,000Source | 16,456,000Source |
| Deferred Revenue, NoncurrentUSD | 0Source | — | — | 0Source | — | — | 2,863,000Source | — | 0Source | 2,863,000Source | 0Source | 5,999,000Source |
| Long-term DebtUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 73,463,000Source | 86,293,000Source | 99,718,000Source | 116,137,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,359,000Source | 3,564,000Source | 6,953,000Source | 8,986,000Source | 9,301,000Source | 7,182,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,160,000Source | -1,227,000Source | -1,375,000Source | 633,000Source | 424,000Source | 453,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,110,000Source | -13,391,000Source | -39,637,000Source | -64,850,000Source | -85,936,000Source | -35,356,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,199,000Source | 11,349,000Source | 15,580,000Source | 22,948,000Source | 50,773,000Source | -74,942,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 182,000Source | 1,008,000Source | 512,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 11,619,000Source | 2,784,000Source | 5,721,000Source | 51,996,000Source | 30,647,000Source | 31,814,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 5,698,000Source | 746,000Source | -18,322,000Source | 10,045,000Source | -4,491,000Source | -78,506,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 22,408,000Source | 31,846,000Source | 19,171,000Source | 37,412,000Source | 23,706,000Source | 37,076,000Source | 18,008,000Source | 36,330,000Source | 26,285,000Source | 30,776,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -10,000Source | 4,000Source | 14,000Source | -49,000Source | 25,000Source | -22,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,202,000Source | 2,160,000Source | 1,595,000Source | 764,000Source | 1,322,000Source | 1,293,000Source | 6,953,000Source | 8,986,000Source | 9,301,000Source | 7,182,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 91,500,000Source | 122,600,000Source | 132,300,000Source | 184,300,000Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | 100,000Source | 100,000Source | 0Source | 0Source | 0Source | 0Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 363,000Source | 1,380,000Source | 1,404,000Source | 1,427,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -12,000Source | 5,000Source | -3,000Source | 21,000Source | -11,000Source | 4,000Source | 14,000Source | -49,000Source | 25,000Source | -22,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 674,000Source | 0Source | 20,000Source | — |
| General and Administrative ExpenseUSD | — | — | 3,044,000Source | 4,537,000Source | 3,867,000Source | 3,328,000Source | 5,889,000Source | 5,832,000Source | 15,893,000Source | 22,108,000Source | 22,475,000Source | 17,834,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | 0Source | 4,444,000Source |
| InterestExpenseNonoperatingUSD | — | — | 23,000Source | 29,000Source | 18,000Source | 28,000Source | 17,000Source | 28,000Source | 97,000Source | 137,000Source | — | — |
| Investment Income, InterestUSD | — | — | 952,000Source | 1,747,000Source | 842,000Source | 1,042,000Source | 815,000Source | 1,197,000Source | 4,068,000Source | 6,585,000Source | 5,688,000Source | 2,192,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,742,000Source | -19,717,000Source | -5,143,000Source | 2,523,000Source | 169,695,000Source | -24,526,000Source | -33,501,000Source | -69,920,000Source | -72,849,000Source | -69,456,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -69,456,000Source |
| Nonoperating Income (Expense)USD | — | — | 917,000Source | 1,723,000Source | 821,000Source | 1,035,000Source | 787,000Source | 1,173,000Source | 4,659,000Source | 6,399,000Source | 5,254,000Source | 444,000Source |
| Operating ExpensesUSD | — | — | 9,188,000Source | 22,779,000Source | 6,978,000Source | 9,251,000Source | 10,218,000Source | 27,463,000Source | 52,243,000Source | 82,490,000Source | 96,244,000Source | 104,475,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 700,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 13,800,000Source | 34,716,000Source | 140,061,000Source | 141,509,000Source | 80,509,000Source | 130,430,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 11,531,000Source | 2,653,000Source | 5,540,000Source | 7,477,000Source | 260,000Source | 122,000Source |
| Depreciation, Depletion and Amortization | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 529,000Source | 1,339,000Source | 1,014,000Source | 10,739,000Source | 179,126,000Source | 1,764,000Source | 14,083,000Source | 6,171,000Source | 18,141,000Source | 39,019,000Source |
| Operating Income (Loss)USD | — | — | -8,659,000Source | -21,440,000Source | -5,964,000Source | 1,488,000Source | 168,908,000Source | -25,699,000Source | -38,160,000Source | -76,319,000Source | -78,103,000Source | -65,456,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | 0Source | 4,444,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,742,000Source | -19,717,000Source | -5,143,000Source | 2,523,000Source | 169,695,000Source | -24,526,000Source | -33,501,000Source | -69,920,000Source | -72,849,000Source | -69,456,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.04Source | -0.1Source | -0.03Source | 0.01Source | 0.88Source | -0.13Source | -0.17Source | -0.38Source | -0.44Source | -0.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | -0.1Source | -0.03Source | 0.01Source | 0.87Source | -0.13Source | -0.17Source | -0.38Source | -0.44Source | -0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 191,778,950Source | 188,997,194Source | 197,470,724Source | 191,551,282Source | 193,768,641Source | 190,707,085Source | 191,599,600Source | 185,608,874Source | 165,960,379Source | 150,939,337Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 191,778,950Source | 188,997,194Source | 197,470,724Source | 192,399,733Source | 195,214,067Source | 190,707,085Source | 191,599,600Source | 185,608,874Source | 165,960,379Source | 150,939,337Source |
| Interest Expense (non-operating)USD | — | — | 23,000Source | 29,000Source | 18,000Source | 28,000Source | 17,000Source | 28,000Source | 97,000Source | 137,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Debt Securities, Realized Gain (Loss)USD | — | — | 100,000Source | 100,000Source | 0Source | 0Source | 0Source | 0Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -12,000Source | 5,000Source | -3,000Source | 21,000Source | -11,000Source | 4,000Source | 14,000Source | -49,000Source | 25,000Source | -22,000Source |
| General and Administrative ExpenseUSD | — | — | 3,044,000Source | 4,537,000Source | 3,867,000Source | 3,328,000Source | 5,889,000Source | 5,832,000Source | 15,893,000Source | 22,108,000Source | 22,475,000Source | 17,834,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | -33,501,000Source | -69,920,000Source | -72,849,000Source | -65,012,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 11,952,000Source | -1,600,000Source | -14,800,000Source | -28,700,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 459,000Source | 1,726,000Source |
| Investment Income, InterestUSD | — | — | 952,000Source | 1,747,000Source | 842,000Source | 1,042,000Source | 815,000Source | 1,197,000Source | 4,068,000Source | 6,585,000Source | 5,688,000Source | 2,192,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -69,456,000Source |
| Nonoperating Income (Expense)USD | — | — | 917,000Source | 1,723,000Source | 821,000Source | 1,035,000Source | 787,000Source | 1,173,000Source | 4,659,000Source | 6,399,000Source | 5,254,000Source | 444,000Source |
| Operating ExpensesUSD | — | — | 9,188,000Source | 22,779,000Source | 6,978,000Source | 9,251,000Source | 10,218,000Source | 27,463,000Source | 52,243,000Source | 82,490,000Source | 96,244,000Source | 104,475,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 700,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 5,778,000Source | 14,273,000Source | 2,898,000Source | 5,498,000Source | 4,120,000Source | 8,959,000Source | 25,241,000Source | 54,037,000Source | 73,700,000Source | 84,408,000Source |
Filing attachments
tm2622329d2_ex99-1.htm · SC TO-I · 2026-08-24
Exhibit 99.1 FORM 51-102F3 Material Change Report Item 1 Name and Address of Issuer Arbutus Biopharma Corporation (“Arbutus” or the “Company”) 701 Veterans Circle Warminster, Pennsylvania USA 18974 Item 2 Date of Material Change August 24, 2026 Item 3 News Release A news release announcing the material change was issued by the Company on August 24, 2026, which was disseminated through the facilities of Globe Newswire and subsequently filed with the SEC at www.sec.gov and SEDA…
Read attachment ↗tm2623751d2_ex99-1.htm · SC TO-C · 2026-08-21
Exhibit 99.1 Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer August 21, 2026 ────────────── Warminster, PA - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purcha…
Read attachment ↗tm2623751d1_ex99-1.htm · 8-K · 2026-08-21
EX-99.1 2 tm2623751d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer August 21, 2026 ────────────── Warminster, PA - Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up …
Read attachment ↗